BioLuminate's Smart Probe Breast Cancer Detection Trials Start In Early 2001
This article was originally published in The Gray Sheet
Executive Summary
San Jose-based BioLuminate expects to be profitable in 2003, immediately following the commercial release of its Smart Probe breast cancer detection diagnostic tool. The privately held start-up began operations in April 2000.
You may also be interested in...
BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year
BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year
Cost-Benefit Evidence For NASA Imaging Tools Needed By Private Sector
The costs associated with bringing National Aeronautics and Space Administration-developed imaging technologies to market for medical diagnostic applications could prove a significant obstacle to device industry involvement, industry and academic panelists suggested at a July 18 workshop in Greenbelt, Maryland.